Search

Your search keyword '"Maurer, Marcus"' showing total 208 results

Search Constraints

Start Over You searched for: Author "Maurer, Marcus" Remove constraint Author: "Maurer, Marcus" Publication Year Range This year Remove constraint Publication Year Range: This year
208 results on '"Maurer, Marcus"'

Search Results

5. A Patient Charter for Chronic Urticaria

9. Definition, acronyms, nomenclature, and classification of angioedema (DANCE): AAAAI, ACAAI, ACARE, and APAAACI DANCE consensus

10. MASK-air: An OECD (Organisation for Economic Co-operation and Development) Best Practice for Public Health on Integrated Care for Chronic Diseases

12. Non–Skin Related Symptoms Are Common in Chronic Spontaneous Urticaria and Linked to Active and Uncontrolled Disease: Results From the Chronic Urticaria Registry

13. Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): Two randomized, double-blind, placebo-controlled, phase 3 trials

15. A Core Outcome Set for Efficacy of Acute Treatment of Hereditary Angioedema

16. Patient-Reported Outcome Measures in Atopic Dermatitis and Chronic Urticaria Are Underused in Clinical Practice

17. Poor Rhinitis and Asthma Control Is Associated With Decreased Health-Related Quality of Life and Utilities: A MASK-air Study

21. Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials

22. Concepts for the Development of Person-Centered, Digitally Enabled, Artificial Intelligence–Assisted ARIA Care Pathways (ARIA 2024)

24. Lanadelumab in Patients 2 to Less Than 12 Years Old With Hereditary Angioedema: Results From the Phase 3 SPRING Study

25. The socio‐economic burden of H1‐antihistamine‐refractory chronic spontaneous urticaria in Germany

27. Usage prevalence of angioedema patient-reported outcome measures: results from the UCARE and ACARE PROMUSE study

30. The Bruton’s Tyrosine Kinase Inhibitor Remibrutinib Exhibits No Impact on Serum Immunoglobulin Levels: Insights from Chronic Spontaneous Urticaria (P10-6.018)

31. Safety of Remibrutinib Across Immune-mediated Diseases Supports Development in Multiple Sclerosis (P8-6.015)

32. Non-Skin-Related Symptoms are Common in Chronic Spontaneous Urticaria and Linked to Active and Uncontrolled Disease: Results from CURE

33. An algorithm for the diagnosis and treatment of chronic inducible urticaria, 2024 update.

34. Disease modification in chronic spontaneous urticaria.

35. In chronic spontaneous urticaria, increased Galectin‐9 expression on basophils and eosinophils is linked to high disease activity, endotype‐specific markers, and response to omalizumab treatment.

36. Plasma proteomics analysis of patients with chronic spontaneous urticaria reveals significant associations with key disease characteristics but not with response to omalizumab treatment.

37. CD4+CCR5+ T cells and CCL3+ mast cells are increased in the skin of patients with chronic spontaneous urticaria.

38. Characterization of cells and mediators associated with pruritus in primary cutaneous T-cell lymphomas.

40. Modelling of patient journey in chronic spontaneous urticaria: Increasing awareness and education by shorten patients' disease journey in Germany

41. Poor rhinitis and asthma control is associated with decreased health-related quality-of-life and utilities: A MASK-air study

42. MASK-air®: An OECD (Organisation for Economic Coordination and Development) Best Practice for Public Health on integrated care for chronic diseases.

43. Monitoring recurrent angioedema: Findings from the Turkish angioedema control test validation study

44. Targeting histamine receptor 4 in cholinergic urticaria with izuforant (LEO 152020): results from a phase IIa randomized double-blind placebo-controlled multicentre crossover trial

45. Enhancing Angioedema Patient Care: Unveiling Underutilization and Barriers in the Implementation of Patient-Reported Outcome Measurements

46. A global perspective on stepping down chronic spontaneous urticaria treatment: Results of the Urticaria Centers of Reference and Excellence SDown‐CSU study

47. Sebetralstat for On-demand Treatment of Hereditary Angioedema Attacks: Results of the Double-blind, Placebo-controlled Phase 3 KONFIDENT Trial

48. Avapritinib Decreased Symptom Burden in Patients With Indolent Systemic Mastocytosis in the Registrational Double-Blind, Placebo-Controlled PIONEER Study

49. Actual real-world application of PROMs in Asthma and Rhinitis as advised by guidelines: PROMUSE Respiratory Study

50. Exploring the Spectrum of Indolent Systemic Mastocytosis: Analysis of High-Risk Disease Features in the PIONEER Study

Catalog

Books, media, physical & digital resources